INVESTMENT IN MARKETABLE SECURITIES

9 Months Ended

Apr. 30, 2021

Cash and Cash Equivalents [Abstract]

INVESTMENT IN MARKETABLE SECURITIES

4. INVESTMENT IN MARKETABLE SECURITIES

On April 13, 2020, in conjunction with the reverse acquisition (see Notes 1 and 3), the Company recorded an initial investment in marketable securities as presented below.

The Company’s investment in marketable securities consists primarily of corporate equities with a quoted market price that are classified as trading securities at April 30, 2021 and July 31, 2020. Marketable securities are stated at fair value as determined by the closing price of each security at each balance sheet date. Unrealized gains and losses on these securities are included in operations for the applicable period.

							Change in
							Fair Value
							For the
	Number						Nine Months
	of		Fair Value at				Ended
	Shares		July 31, 2020		April 30, 2021		April 30, 2021
Common Shares of Entest Group, Inc. (ENTI)		66,667	$	260	$	1,266	$	1,006
Common Shares of Regen Biopharma, Inc. (RGBP)		29,076,665		5,814		561,180		555,366
Series A Preferred Shares of Regen Biopharma, Inc. (RGBPP)		2,907,666		4,362		171,552		167,190
Total			$	10,436	$	733,998	$	723,562